JP7721539B2 - 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法 - Google Patents

多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Info

Publication number
JP7721539B2
JP7721539B2 JP2022542858A JP2022542858A JP7721539B2 JP 7721539 B2 JP7721539 B2 JP 7721539B2 JP 2022542858 A JP2022542858 A JP 2022542858A JP 2022542858 A JP2022542858 A JP 2022542858A JP 7721539 B2 JP7721539 B2 JP 7721539B2
Authority
JP
Japan
Prior art keywords
aba
polysaccharide
group
derivative
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022034889A5 (https=
JPWO2022034889A1 (https=
Inventor
大知 伊藤
誠一 太田
蟠 戚
アーヴィンド クマー シン チャンデル
三津子 伊佐次
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
University of Tokyo NUC
Original Assignee
Mochida Pharmaceutical Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd, University of Tokyo NUC filed Critical Mochida Pharmaceutical Co Ltd
Publication of JPWO2022034889A1 publication Critical patent/JPWO2022034889A1/ja
Publication of JPWO2022034889A5 publication Critical patent/JPWO2022034889A5/ja
Priority to JP2025126877A priority Critical patent/JP2025156408A/ja
Application granted granted Critical
Publication of JP7721539B2 publication Critical patent/JP7721539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/14—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups
    • C08B11/15—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with nitrogen-containing groups with carbamoyl groups, i.e. -CO-NH2
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022542858A 2020-08-14 2021-08-10 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法 Active JP7721539B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025126877A JP2025156408A (ja) 2020-08-14 2025-07-30 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020137010 2020-08-14
JP2020137010 2020-08-14
PCT/JP2021/029573 WO2022034889A1 (ja) 2020-08-14 2021-08-10 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025126877A Division JP2025156408A (ja) 2020-08-14 2025-07-30 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Publications (3)

Publication Number Publication Date
JPWO2022034889A1 JPWO2022034889A1 (https=) 2022-02-17
JPWO2022034889A5 JPWO2022034889A5 (https=) 2024-04-09
JP7721539B2 true JP7721539B2 (ja) 2025-08-12

Family

ID=80247958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542858A Active JP7721539B2 (ja) 2020-08-14 2021-08-10 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法
JP2025126877A Pending JP2025156408A (ja) 2020-08-14 2025-07-30 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025126877A Pending JP2025156408A (ja) 2020-08-14 2025-07-30 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法

Country Status (8)

Country Link
US (1) US20230285577A1 (https=)
EP (1) EP4198060A4 (https=)
JP (2) JP7721539B2 (https=)
KR (1) KR20230061346A (https=)
CN (2) CN116322642B (https=)
AU (1) AU2021324708A1 (https=)
CA (1) CA3188951A1 (https=)
WO (1) WO2022034889A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023157150A1 (ja) * 2022-02-16 2023-08-24 持田製薬株式会社 多糖誘導体の用途
CN115991883B (zh) * 2022-12-26 2024-07-16 四川大学华西医院 一种用于消化道esd的水凝胶及其制备方法和用途
CN120267903B (zh) * 2025-06-06 2025-08-08 吉林大学 一种免疫调控水凝胶及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114602A1 (en) 2009-06-16 2012-05-10 Fidia Farmaceutici S.P.A. Process for the synthesis of conjugates of glycosaminoglycanes (gag) with biologically active molecules, polymeric conjugates and relative uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2855307B2 (ja) * 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
JP4565691B2 (ja) 2000-02-28 2010-10-20 株式会社Phg ヘパリン結合性成長因子用徐放基材、およびヘパリン結合性成長因子徐放剤
RU2283848C1 (ru) * 2005-06-16 2006-09-20 Институт нефтехимии и катализа РАН Республика Башкортостан Способ получения конъюгатов альгиновой кислоты
ITMI20061726A1 (it) * 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
JPWO2008096547A1 (ja) * 2007-02-07 2010-05-20 焼津水産化学工業株式会社 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
EP3778653B1 (en) 2018-03-28 2025-07-09 Mochida Pharmaceutical Co., Ltd. Novel reactive alginic acid derivatives
JP7088075B2 (ja) 2019-02-22 2022-06-21 株式会社デンソー 電子制御装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114602A1 (en) 2009-06-16 2012-05-10 Fidia Farmaceutici S.P.A. Process for the synthesis of conjugates of glycosaminoglycanes (gag) with biologically active molecules, polymeric conjugates and relative uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUFFA,R. et al.，Conjugates of modified hyaluronic acid with amino compounds for biomedical applications，Carbohydrate Polymers，2018年，Vol.189，pp.273-279，DOI 10.1016/j.carbpol.2018.02.048
DELLACHERIE,E. et al.，A new approach to aldehydic dextrans，Polymer Bulletin，1993年，Vol.31, No.2，pp.145-149，DOI 10.1007/BF00329959
LI,N. et al.，Using casein and oxidized hyaluronic acid to form biocompatible composite hydrogels for controlled d，Materials Science & Engineering, C，2014年，Vol.36，pp.287-293，DOI 10.1016/j.msec.2013.12.025
LIU,C. et al.，Multifunctional PEG-grafted chitosan copolymer possessing amino and carboxyl (or formyl) groups，Central European Journal of Chemistry，2010年，Vol.8, No.3，pp.576-581，DOI 10.2478/s11532-010-0013-3

Also Published As

Publication number Publication date
CA3188951A1 (en) 2022-02-17
CN116322642B (zh) 2024-08-23
EP4198060A4 (en) 2024-09-04
EP4198060A1 (en) 2023-06-21
US20230285577A1 (en) 2023-09-14
JPWO2022034889A1 (https=) 2022-02-17
AU2021324708A1 (en) 2023-03-09
JP2025156408A (ja) 2025-10-14
KR20230061346A (ko) 2023-05-08
WO2022034889A1 (ja) 2022-02-17
CN118955760A (zh) 2024-11-15
CN116322642A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
Zafar et al. Role of crosslinkers for synthesizing biocompatible, biodegradable and mechanically strong hydrogels with desired release profile
Qian et al. Injectable and self-healing polysaccharide-based hydrogel for pH-responsive drug release
JP7830616B2 (ja) 多糖誘導体の用途
JP2025156408A (ja) 多糖誘導体、多糖誘導体－薬物コンジュゲート、その製造方法
Tan et al. Controlled gelation and degradation rates of injectable hyaluronic acid‐based hydrogels through a double crosslinking strategy
Fan et al. Cytocompatible in situ forming chitosan/hyaluronan hydrogels via a metal-free click chemistry for soft tissue engineering
Tan et al. Injectable in situ forming biodegradable chitosan–hyaluronic acid based hydrogels for cartilage tissue engineering
US7651702B2 (en) Crosslinking hyaluronan and chitosanic polymers
JP6178399B2 (ja) 求核的に活性化したポリオキサゾリンに由来する架橋ポリマー及び医療製品
US7740883B2 (en) Nanoparticles from chitosan
WO2009006780A1 (en) A method for the formation of a rapid-gelling biocompatible hydrogel and the preparation of a spraying agent
JP2009537597A (ja) アニオン性及びカチオン性多糖類のポリマー混合物並びにその使用
CN102585303A (zh) 一种壳聚糖/聚赖氨酸原位凝胶及其制备方法
WO2008067655A1 (en) Biocompatible hydrogel-based scaffolds
Tsai et al. Injectable, shear-thinning, self-healing, and self-cross-linkable benzaldehyde-conjugated chitosan hydrogels as a tissue adhesive
US7879818B2 (en) Hyaluronic acid-based cross-linked nanoparticles
Youn et al. Tissue adhesives based on chitosan for biomedical applications
JP2023081477A (ja) 多糖誘導体、多糖誘導体を含む架橋構造体、架橋構造体の製造方法
CN103524748B (zh) 聚氨基酸接枝共聚物及其制备方法、可注射性水凝胶
RU2713295C2 (ru) Способ сшивания полисахаридов при помощи фотоудаляемых защитных групп
AU2012313983B2 (en) Multilayer implants for delivery of therapeutic agents
CN106750416A (zh) 一种拥有自愈合和pH响应性能的可注射水凝胶及其制备方法和应用
RU2708327C2 (ru) Производные сульфатированных полисахаридов, их способ получения, модификация и применение
KR102869207B1 (ko) 주사 가능한 pH-반응성 하이드로겔
US9795717B2 (en) Enzymatically degradable compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250730

R150 Certificate of patent or registration of utility model

Ref document number: 7721539

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150